Literature DB >> 29276262

Formulary Drug Reviews: Plecanatide.

Danial E Baker1.   

Abstract

Entities:  

Year:  2017        PMID： 29276262      PMCID： PMC5735701          DOI： 10.1177/0018578717717623

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  9 in total

Review 1.  Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.

Authors:  M Camilleri
Journal:  Clin Pharmacol Ther       Date:  2011-11-09       Impact factor: 6.875

2.  Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.

Authors:  A Jarmuż; M Zielińska; M Storr; J Fichna
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

Review 3.  American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.

Authors:  Alexander C Ford; Paul Moayyedi; Brian E Lacy; Anthony J Lembo; Yuri A Saito; Lawrence R Schiller; Edy E Soffer; Brennan M R Spiegel; Eamonn M M Quigley
Journal:  Am J Gastroenterol       Date:  2014-08       Impact factor: 10.864

4.  The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Evaluation and Management of Constipation.

Authors:  Ian M Paquette; Madhulika Varma; Charles Ternent; Genevieve Melton-Meaux; Janice F Rafferty; Daniel Feingold; Scott R Steele
Journal:  Dis Colon Rectum       Date:  2016-06       Impact factor: 4.585

5.  Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.

Authors:  Kunwar Shailubhai; Stephen Comiskey; John A Foss; Rong Feng; Laura Barrow; Gail M Comer; Gary S Jacob
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

Review 6.  Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

Authors:  Khaled A Jadallah; Susan M Kullab; David S Sanders
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

7.  Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

Authors:  Kunwar Shailubhai; Vaseem Palejwala; Krishna Priya Arjunan; Sayali Saykhedkar; Bradley Nefsky; John A Foss; Stephen Comiskey; Gary S Jacob; Scott E Plevy
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

8.  Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide.

Authors:  Robert W Busby; Stephan Ortiz
Journal:  Dig Dis Sci       Date:  2014-03-21       Impact factor: 3.199

Review 9.  Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.

Authors:  Giovanni M Pitari
Journal:  Drug Des Devel Ther       Date:  2013-04-19       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.